TNFSF11 and Miyoshi myopathy: There is an increasing amount of preclinical and clinical evidence showing that a new, promising anti-catabolic agent, denosumab (AMG 162, a human monoclonal antibody to receptor activator of nuclear factor-κB ligand (RANKL)), is able to improve MM-induced bone disease [19]–[21].